|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-12-14
|
|
pubmed:abstractText |
Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1557-8518
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8 Suppl 1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
S1-2
|
|
pubmed:dateRevised |
2011-7-20
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Bile acid sequestrants and diabetes: introduction and overview to the supplement.
|
|
pubmed:affiliation |
Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California, USA.
|
|
pubmed:publicationType |
Research Support, N.I.H., Extramural,
Introductory Journal Article
|
